Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The Virtual iwAL workshop will be held between the 28th and 30th of April 2021. The program will focus on important questions in the field of research and clinical advances in ALL and AML as well as related hematological malignancies, showcasing stimulating and insightful content, as well as live interactive debate and panel sessions.
10:00am EST Welcome Day 1: Dieter Hoelzer/Daniel DeAngelo
10.00-10.50 Session 1: Advances in T-ALL | Chairs: Jan Cools & Daniel DeAngelo
Panel Discussion
10.50-11.50 Session 2: B-ALL | Chairs: Charles Mullighan & Robin Foa
Panel Discussion
11:50-12:30 Session 3: MRD and diagnostics | Chairs: Sabina Chiaretti & Gianni Cazzaniga
Panel Discussion
12:30-13:10 Session 4: Immunotherapies| Chairs: Robin Foa & Daniel DeAngelo
Panel Discussion
13:10-13:45 Session 5: CAR T-cell therapy in ALL | Chairs: Dieter Hoelzer & Sabina Chiaretti
Panel Discussion
End Day 1, Conclusions & Wrap up
10:00am EST Welcome and Introductions: Richard Stone and Mark Levis
10:00-10:50 Session 6: Advances in AML biology | Chairs: Marina Konopleva & Ravi Majeti
Panel Discussion
10:50-11:40 Session 7: Controversies in AML | Chairs: Richard Stone & Andrew Wei
Panel Discussion
Panel Discussion
11:40-12:40 Session 8: ASCT and post-ASCT maintenance approaches | Chairs: Charles Craddock & Sergio Giralt
Panel Discussion
12:40-13:40 Session 9: MDS new data/novel therapies | Chairs: Amer Zeidan & Guillermo Garcia-Manero
End Day 2, Conclusion & Wrap up
10:00am EST Welcome and Introductions
10:00-10:50 Session 10: Mechanisms of drug resistance | Chairs: Jessica Altman & Andrew Wei
Panel Discussion
10:50-11:40 Session 11: To target or not in elderly AML | Chairs: Mark Levis & Farhad Ravandi
Should FLT3 inhibitors be used in all frontline FLT3 AML not eligible for intensive therapy?
Panel Discussion
Is HMA-VEN or HMA-IDH inhibitor the optimal frontline therapy for frontline IDHm AML not eligible for intensive therapy?
Panel Discussion
11:40-12:30 Session 12: Emerging therapies in AML | Chairs: Gail Roboz & Courtney DiNardo
Panel Discussion
12:30-13:30 Session 13: Immunotherapeutics in AML | Chairs: Naval Daver & Amir Fathi
Panel Discussion
End Day 3, Conclusion & Wrap up
ENDS